Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Asthma (Positioning of Current and Emerging Agents) | Physician & Payer Forum | Brazil and Mexico | 2014
Several newly approved agents for asthma together with others seeking approval are expanding the range of therapeutic options for this disease in Brazil and Mexico. Drugs such as the inhaled…
Asthma (What Are the Expectations for Optimal Positioning of New and Emerging Inhaled and Biological Therapies in Market Access Systems?) | Physician & Payer Forum | EU5 | 2014
High unmet need exists for severe, refractory asthma patients, for whom Genentech/Novartis’s Xolair is currently the only therapeutic option. Together with a number of newly approved agents for…
Convenient Once-daily Fixed-dose Combination Inhaler and Late-Stage Emerging Biologics in Asthma: How Will U.S. Payers and Prescribers Manage Different Segments of the Asthma Market? | Physician & Payer Forum | US | 2014
Asthma is a chronic inflammatory disorder of the airways leading to recurring episodes of wheezing, breathlessness, chest tightness, and coughing, with episodes characterized by airflow obstruction…
Asthma (Healthcare Reform and Asthma: How Should Brand Marketers Adapt to the Launch of Exchanges and Expanded Medicaid?) | Physician & Payer Forum | US | 2014
Large portions of the Affordable Care Act (ACA) took effect in 2014, giving millions of Americans access to health insurance and prescription drug coverage for the first time in years. This report…
